NCT01067417

Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: Medical Research Council · Other Government
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot study is to find out if taking hydroxychloroquine will decrease immune activation (stimulation of the body's defence system) in people with early HIV infection. Hydroxychloroquine is a medicine that has been used successfully for many years to treat autoimmune diseases (diseases in which the immune system causes damage to the body), e.g. lupus and rheumatoid arthritis. It is generally safe in long-term use and easily accessible. The immune system is stimulated in response to infections including HIV, so treatments that decrease immune activation may have long-term clinical benefits i.e. delay onset of treatment.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Taken orally 2x200mg capsules once daily for 48 weeks
DRUG	Placebo	Taken orally 2x200mg capsules once daily for 48 weeks

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2010-02-11
• Last updated: 2010-07-30